Scout Investments’s Acorda Therapeutics ACOR Stock Holding History

Scout Investments’s Portfolio ACOR Stock Details ACOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-384	Closed	-$987K	–	303
2017 Q4	$987K	Sell	384 -27	-7%	-$76.8K	0.02%	277
2017 Q3	$1.17M	Hold	411	–	–	0.03%	273
2017 Q2	$971K	Buy	411 +6	+1%	+$11.9K	0.03%	270
2017 Q1	$1.02M	Sell	405 -1	-0.2%	-$2.88K	0.03%	263
2016 Q4	$915K	Sell	406 -216	-35%	-$514K	0.03%	262
2016 Q3	$1.56M	Hold	622	–	–	0.04%	243
2016 Q2	$1.9M	Buy	622 +1	+0.2%	+$3.25K	0.05%	226
2016 Q1	$1.97M	Hold	621	–	–	0.05%	219
2015 Q4	$3.19M	Sell	621 -35	-5%	-$153K	0.08%	190
2015 Q3	$2.09M	Hold	656	–	–	0.05%	211
2015 Q2	$2.62M	Hold	656	–	–	0.05%	217
2015 Q1	$2.62M	Sell	656 -3,239	-83%	-$14.8M	0.04%	218
2014 Q4	$19.1M	Sell	3,895 -1,434	-27%	-$6.15M	0.29%	109
2014 Q3	$21.7M	Sell	5,329 -357	-6%	-$1.34M	0.29%	102
2014 Q2	$23M	Buy	5,686 +95	+2%	+$387K	0.27%	107
2014 Q1	$25.4M	Buy	5,591 +101	+2%	+$408K	0.29%	97
2013 Q4	$19.2M	Buy	5,490 +58	+1%	+$226K	0.22%	113
2013 Q3	$22.3M	Buy	5,432 +256	+5%	+$1.1M	0.16%	156
2013 Q2	$20.5M	Buy	+5,176	New	+$21.3M	0.24%	115

Other funds holding ACOR

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HEC

Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Scout Investments's ACOR Position: Q1 2018 in Review

Scout Investments sold out of Acorda Therapeutics (ACOR) in Q1 2018, closing a stake of 384 shares — an estimated $987K sold.

Scout Investments first reported a position in ACOR in Q2 2013 and held it in 19 quarters. The position peaked at $25.4M in Q1 2014. 162 funds tracked by Wall St. Rank hold ACOR as of Q1 2018.

Scout Investments reported no remaining Acorda Therapeutics position as of Q1 2018 after selling out during the quarter.
Scout Investments sold 384 Acorda Therapeutics shares in Q1 2018, an estimated $987K.
Scout Investments first reported a position in Acorda Therapeutics in Q2 2013 and held it in 19 quarters.
Scout Investments's Acorda Therapeutics position peaked at $25.4M in Q1 2014.
162 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q1 2018.

Based on Scout Investments's 13F filing for Q1 2018, filed 9 May 2018.